ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 138.2 BRL | -2.10% |
|
+1.23% | +47.92% |
| May. 28 | Annual sales of weight-loss drugs seen hitting $150 billion | RE |
| May. 28 | Weight-loss drug forecasts jump to $150 billion as supply grows | RE |
| Sales 2024 * | 43B 222B | Sales 2025 * | 52.61B 272B | Capitalization | 727B 3,753B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 61.6B | Net income 2025 * | 16.55B 85.46B | EV / Sales 2024 * | 17.4 x |
| Net Debt 2024 * | 19.98B 103B | Net Debt 2025 * | 15.29B 78.92B | EV / Sales 2025 * | 14.1 x |
| P/E ratio 2024 * |
60.4
x | P/E ratio 2025 * |
43.5
x | Employees | 43,000 |
| Yield 2024 * |
0.64% | Yield 2025 * |
0.74% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -2.10% | ||
| 1 week | +1.23% | ||
| Current month | +1.99% | ||
| 1 month | +10.20% | ||
| 3 months | +10.57% | ||
| 6 months | +44.25% | ||
| Current year | +47.92% |
1 week
135.70
141.35
1 month
123.52141.35
Current year
94.16141.35
1 year
69.46141.35
3 years
33.67141.35
5 years
13.56141.35
10 years
4.39141.35
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 138.2 | -2.10% | 58,133 |
| 24-05-27 | 141.2 | +0.62% | 1,255 |
| 24-05-24 | 140.3 | +0.70% | 17,076 |
| 24-05-23 | 139.3 | +1.12% | 4,901 |
| 24-05-22 | 137.8 | +0.92% | 2,954 |
Delayed Quote Sao Paulo, May 28, 2024 at 04:10 pm EDT
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.9
USD
Average target price
850.8
USD
Spread / Average Target
+5.31%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.89% | 354B | |
| +15.66% | 328B | |
| +0.24% | 277B | |
| +13.47% | 243B | |
| +7.35% | 205B | |
| -6.42% | 203B | |
| +4.23% | 164B | |
| -1.70% | 164B | |
| -1.31% | 122B |
- Stock Market
- Equities
- LLY Stock
- LILY34 Stock
